Prostacyclin analog

This page covers all Prostacyclin analog drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Prostacyclin receptor (IP receptor), IP receptor.

Targets

Prostacyclin receptor (IP receptor) · IP receptor

Marketed (1)

• FLOLAN injection with reformulated diluent · GlaxoSmithKline · Cardiovascular
  Epoprostenol (prostacyclin) directly relaxes vascular smooth muscle and inhibits platelet aggregation to reduce pulmonary vascular resistance.

Phase 3 pipeline (5)

• Iloprost (Ventavis) · Ludwig-Maximilians - University of Munich · Cardiovascular
  Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation.
• Iloprost Injection, for intravenous use · Civi Biopharma, Inc. · Cardiovascular
  Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, promoting vasodilation and inhibiting platelet aggregation.
• preservative-free parenteral treprostinil · AOP Orphan Pharmaceuticals AG · Cardiovascular
  Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.
• L606 · Liquidia Technologies, Inc. · Pulmonary Hypertension
  L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.
• LIQ861 Inhaled Treprostinil · Liquidia Technologies, Inc. · Cardiovascular / Pulmonary Hypertension
  LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.

Phase 2 pipeline (1)

• Beraprost Sodium Modified Release · Lung Biotechnology PBC · Cardiovascular
  Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation.